Newsroom

Strive to Deliver Breakthroughs

  1. March 12, 2025

    Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – March 12, 2025   - Élancé Therapeutics aims to improve current obesi...

    View more
  2. March 11, 2025

    Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 10, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...

    View more
  3. March 11, 2025

    Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 10, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...

    View more
  4. February 26, 2025

    HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 25, 2025   HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company inc...

    View more
  5. February 20, 2025

    Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 20, 2025   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceut...

    View more
  6. February 14, 2025

    Harbour BioMed Announces Business Progress and Update

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – February 13, 2025   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceu...

    View more
  7. February 05, 2025

    Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 4, 2025   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceuti...

    View more
  8. January 10, 2025

    Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025   Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...

    View more
  9. November 15, 2024

    Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...

    View more
  10. November 08, 2024

    Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...

    View more